Despite the encouraging preclinical results showing significant antitumor activity and favorable safety profile in mice and monkeys bearing KRAS-mutant lung cancer, the first phase I clinical trial (NCT03101839) failed, possibly because AZD4785 targets both mutant and wild type KRAS protein [3, 118]. This evidence concerns the gene KRAS and lung cancer.